Document Detail

Ex vivo evaluation of pidotimod activity in patients with chronic obstructive pulmonary disease.
MedLine Citation:
PMID:  7857352     Owner:  NLM     Status:  MEDLINE    
The aim of this study was to evaluate the activity of pidotimod ((R)-3-[(S)-(5-oxo-2-pyrrolidinyl)carbonyl]-thiazolidine-4-carboxylic acid, PGT/1A, CAS 121808-62-6) on 52 patients affected with chronic obstructive pulmonary disease (COPD). The study was carried out in a randomized, parallel, double-blind trial, followed by incomplete blocks design. Pidotimod 800 mg was administered orally twice a day for 30 days. The follow-up period was 5 weeks. Our results show that in patients with COPD pidotimod potentiates T-cell activity. The effects on T-cells appear after 15 days of treatment and last for 5 weeks after the end of therapy. Since other studies demonstrated that pidotimod displays an immunopotentiating activity also on macrophages and granulocytes, the drug is useful to increase the immune defense during infections. The drug has a good compliance and is well tolerated also during long-term treatment.
G P Benetti; M T Illeni; A Passera; G Bombelli; G Lavecchia; C Uslenghi
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Arzneimittel-Forschung     Volume:  44     ISSN:  0004-4172     ISO Abbreviation:  Arzneimittelforschung     Publication Date:  1994 Dec 
Date Detail:
Created Date:  1995-03-16     Completed Date:  1995-03-16     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0372660     Medline TA:  Arzneimittelforschung     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  1503-5     Citation Subset:  IM    
1st Medical Department, Predabissi Hospital, Milan, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adjuvants, Immunologic / adverse effects,  therapeutic use*
Aged, 80 and over
Double-Blind Method
Follow-Up Studies
Granulocytes / drug effects,  immunology
Lung Diseases, Obstructive / drug therapy*,  immunology
Lymphocyte Activation / drug effects
Lymphocytes / drug effects,  immunology
Macrophages / drug effects,  immunology
Middle Aged
Pyrrolidonecarboxylic Acid / adverse effects,  analogs & derivatives*,  therapeutic use
Thiazoles / adverse effects,  therapeutic use*
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/Thiazoles; 0/Thiazolidines; 117241-40-4/pidotimod; 98-79-3/Pyrrolidonecarboxylic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Evaluation of the efficacy of pidotimod in the exacerbations in patients affected with chronic bronc...
Next Document:  Role of immunoactivation with pidotimod in recurrent respiratory infections in childhood.